Varian secures IDE for new Flash clinical trial

By staff writers

June 28, 2022 -- Siemens Healthineers radiation therapy unit Varian has received an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) for a new clinical trial evaluating its Flash therapy technology.

Building on clinical evidence from the initial FeAsibility Study of Flash therapy for the Treatment of Symptomatic Bone Metastases (FAST-01) clinical trial, FAST-02 will include bone metastases in the chest, according to Varian.

The trial, which will be conducted at Cincinnati Children's/UC Health Proton Therapy Center, is expected to enroll 10 patients with painful thoracic bone metastases. Led by principal investigator Dr. John Breneman, the researchers will assess treatment-related side effects and treatment efficacy, Varian said.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking